Patents by Inventor Luc Montagnier

Luc Montagnier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6054565
    Abstract: A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These reagents include cDNA probes which are capable of hybridizing to at least a portion of the genome of HIV-2. In the embodiment, the DNA probes are capable of hybridizing to the entire genome of HIV-2. These reagents also include polypeptides encoded by some of these DNA sequences.
    Type: Grant
    Filed: April 28, 1994
    Date of Patent: April 25, 2000
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Luc Montagnier, Denise Geutard, Francois Clavel, Pierre Sonigo, Mireille Guyader
  • Patent number: 6048685
    Abstract: The molecular cloning and characterization of a novel human immunodeficiency virus type 2 (HIV-2), designated HIV-2.sub.ROD, is described. A recombinant .lambda. phage genomic library was screened with an HIV-2-specific probe to identify overlapping subgenomic clones. Fragments of these .lambda. phage clones were subcloned into a suitable vector to reconstitute the complete HIV-2.sub.ROD genome. The complete nucleotide sequence of this proviral clone was ascertained and the following genes and gene products identified: gag (including p16, p26, and p12), pol, vif, vpr, vpx, env, tat, rev, and nef. These gene products will be useful, inter alia, in in vitro diagnostic methods and kits for the detection of HIV-2-specific antisera.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: April 11, 2000
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Luc Montagnier, Denise Geutard, Francois Clavel, Pierre Sonigo, Mireille Guyader
  • Patent number: 6037165
    Abstract: Methods for producing the newly discovered HIV-2 retrovirus and its antigens are provided. The antigens are obtained from various HIV-2 retroviruses. The antigen compositions comprise a lysate of an HIV-2 retrovirus, a protein of an HIV-2 retrovirus, or a glycoprotein of an HIV-2 retrovirus. Specifically, the antigen composition can comprise p12, p16, p26, gp32, gp42, and gp140.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: March 14, 2000
    Assignee: Institut Pasteur
    Inventors: Luc Montagnier, Solange Chamaret, Denise Guetard, Marc Alizon, Fran.cedilla.ois Clavel, Mireille Guyader, Pierre Sonigo, Fran.cedilla.oise Brun-Vezinet, Marianne Rey, Christine Rouzioux, Christine Katlama
  • Patent number: 5976785
    Abstract: A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These reagents include cDNA probes which are capable of hybridizing to at least a portion of the genome of HIV-2. In one embodiment, the DNA probes are capable of hybridizing to the entire genome of HIV-2. These reagents also include polypeptides encoded by some of these DNA sequences.
    Type: Grant
    Filed: December 20, 1991
    Date of Patent: November 2, 1999
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Luc Montagnier, Denise Guetard, Francois Clavel, Pierre Sonigo, Mireille Guyader
  • Patent number: 5889158
    Abstract: This invention discloses the identification and characterization of a novel human retrovirus, originally designated lymphadenopathy-associated virus type II, or LAV-II, and subsequently redesignated the human immunodeficiency virus type 2, or HIV-2. This virus was isolated from West African AIDS patients and propagated on immortalized lymphocytic cell lines or donor peripheral blood mononuclear cells (PBMCs). Immunological and nucleic acid hybridization studies demonstrated that HIV-2 differs significantly from HIV-1, the aetiological agent of AIDS. Additional biochemical characterization identified viral antigens having molecular weights of 16, 26, 36, and 130-140 kDa, as determined by SDS-PAGE. These proteins were subsequently designated p16, p26, gp36, and gp130-140, respectively. These antigens can be employed, inter alia, in the generation of both polyclonal and monoclonal antibodies, which should prove useful in diagnostic and viral antigen purification applications.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: March 30, 1999
    Assignee: Institut Pasteur
    Inventors: Luc Montagnier, Denise Guetard, Francoise Brun-Vezinet, Francois Clavel
  • Patent number: 5869631
    Abstract: A variant of a LAV virus, designated LAV.sub.ELI and capable of causing. AIDS. The cDNA and antigens of the LAV.sub.ELI virus can be used for the diagnosis of AIDS and pre-AIDS.
    Type: Grant
    Filed: February 19, 1991
    Date of Patent: February 9, 1999
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Pierre Sonigo, Simon Wain-Hobson, Luc Montagnier
  • Patent number: 5866319
    Abstract: A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These reagents include cDNA probes which are capable of hybridizing to at least a portion of the genome of HIV-2. In one embodiment, the DNA probes are capable of hybridizing to the entire genome of HIV-2. These reagents also include polypeptides encoded by some of these DNA sequences.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: February 2, 1999
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Luc Montagnier, Denise Guetard, Francois Clavel, Pierre Sonigo, Mireille Guyader
  • Patent number: 5858651
    Abstract: A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These reagents include cDNA probes which are capable of hybridizing to at least a portion of the genome of HIV-2. In one embodiment, the DNA probes are capable of hybridizing to the entire genome of HIV-2. These reagents also include polypeptides encoded by some of these DNA sequences.
    Type: Grant
    Filed: May 26, 1994
    Date of Patent: January 12, 1999
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Luc Montagnier, Denise Geutard, Francois Clavel, Pierre Sonigo, Mireille Guyader
  • Patent number: 5843638
    Abstract: This invention is directed to nucleic acids derived from the pol region of the genome of human immunodeficiency virus type 1 (HIV-1). The nucleic acids are useful as probes for the detection of HIV-1. More particularly, this invention is directed to nucleic acids encoding a pol region of HIV-1 extending from about nucleotide 1856 to about 1906 and extending from about nucleotide 2048 to about nucleotide 2797.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 1, 1998
    Assignee: Institut Pasteur and Centre National de la Recherche Scientifique
    Inventors: Luc Montagnier, Bernard Krust, Solange Chamaret, Fran.cedilla.ois Clavel, Jean-Claude Chermann, Fran.cedilla.oise Barre-Sinoussi, Marc Alizon, Pierre Sonigo, Stewart Cole, Olivier Danos, Simon Wain-Hobson
  • Patent number: 5830641
    Abstract: The invention relates to a new class of retroviruses, designated by HIV-2, of which samples have been deposited to the ECACC under numbers 87.01.1001 and 87.01.1002 and to the NCIB under numbers 12.398 and 12.399.It relates also to antigens capable to be obtained from this virus, particularly proteins p12, p16, p26 and gp140. These various antigens can be used for the diagnosis of the disease, especially by contacting these antigens with a serum of a patient submitted to the diagnosis.It relates to immunogenic compositions containing more particularly the glycoprotein gp140. Finally it concerns nucleotidic sequences, which can be used especially as hybridization probes, derived from the RNA of HIV-2.
    Type: Grant
    Filed: March 17, 1994
    Date of Patent: November 3, 1998
    Assignee: Institut Pasteur
    Inventors: Luc Montagnier, Denise Guetard, Marc Alizon, Fran.cedilla.ois Clavel, Mireille Guyader, Pierre Sonigo
  • Patent number: 5824482
    Abstract: An HIV isolate, LAV.sub.MAL, has been purified, sequenced, and characterized at the genetic level. The entire nucleic acid sequence of the viral genome, the encoded amino acid sequences, and the open reading frames found in the genome are disclosed. Specific peptides relating to the envelope glycoprotein of the viral genome are discussed. These peptides can be used in diagnostic methods and kits for detecting the presence of an HIV virus.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 20, 1998
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Pierre Sonigo, Simon Wain-Hobson, Luc Montagnier
  • Patent number: 5807992
    Abstract: Characterization of the envelope transmembrane protein of human immunodeficiency virus type 2 (HIV-2) was carried out using murine polyclonal and monoclonal antibodies or patient sera specific for HIV-2 proteins. A 80-Mr glycoprotein (gp80) was produced in HIV-2 infected cells along with three other glycoproteins that were recently reported: the extracellular glycoprotein (gp125), the envelope glycoprotein precursor (gp140), and the transient dimeric form of gp140 (gp300). The gp125 and gp80 were detectable after the synthesis of gp140 and the formation of gp300. Among these four glycoproteins, only gp80 and gp125 were associated with HIV-2 virions. As the other glycoproteins, gp8O was recognized by all HIV-2 positive sera. A murine polyclonal antibody raised against the purified gp300 recognized all four glycoproteins.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 15, 1998
    Assignee: Institut Pasteur
    Inventors: Ara G. Hovanessian, Marie-Anne Rey, Anne G. Laurent, Bernard Krust, Luc Montagnier
  • Patent number: 5795577
    Abstract: This invention relates to an immunogenic composition comprising a viral vector. The genome of the viral vector comprises a functional origin of replication of a poxvirus, a DNA fragment encoding a non-cleavable gp160, a DNA fragment encoding a signal peptide, and a promoter for expressing DNA fragments in mammalian cells.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 18, 1998
    Assignees: Transgene S.A., Institut Pasteur
    Inventors: Marie-Paule Kieny, Guy Rautmann, Jean-Pierre Lecocq, Simon Wain Hobson, Marc Girard, Luc Montagnier
  • Patent number: 5786177
    Abstract: The invention relates to nucleotidic sequences derived from genomes of the HIV-1 type virus, or from genomes of the HIV-2 type virus, or of the SIV type virus, and their applications, especially as oligonucleotidic initiators of implementation of an (in vitro) method for the diagnosis of the infection of an individual by a virus of the HIV-1 and/or HIV-2 type.
    Type: Grant
    Filed: July 16, 1997
    Date of Patent: July 28, 1998
    Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale
    Inventors: Maurice Moncany, Luc Montagnier
  • Patent number: 5773602
    Abstract: A novel human immunodeficiency virus type 1 (HIV-1) isolate, designated lymphadenopathy-associated virus strain MAL, or LAV.sub.MAL, was molecularly cloned and characterized. Nucleotide sequence analysis demonstrated that the viral genome of LAV.sub.MAL is 9229 nucleotides long. This retrovirus contains the canonical gag, pol, and env genes, as well as ancillary genes encoding Vif (or Q), Vpr (or R), Tat (or S), and Nef (or F). This virus differs significantly, at both the nucleotide and amino acid sequence levels, from prototypical HIV isolates (e.g., HTLV-III, LAV.sub.BRU, and ARV). DNA fragments corresponding to the various gene products and regulatory regions are disclosed. These fragments are useful, inter alia, as probes in diagnostic assays and for the generation of recombinant proteins.
    Type: Grant
    Filed: November 18, 1993
    Date of Patent: June 30, 1998
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Pierre Sonigo, Simon Wain-Hobson, Luc Montagnier
  • Patent number: 5770703
    Abstract: The inventors disclose nucleic acids of HIV-2 encoding the entire envelope glycoprotein and peptide regions thereof. Also described are purified and cloned nucleic acids having the entire HIV-2 genome. The nucleic acids can be used to produce polypeptides corresponding to the HIV-2 envelope gene or peptides from specific regions of the HIV-2 envelope gene. Uses in hybridization assays are also disclosed.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: June 23, 1998
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Luc Montagnier, Denise Geutard, Francois Clavel, Pierre Sonigo, Mireille Guyader
  • Patent number: 5747242
    Abstract: A variant of a LAV virus, designated LAV.sub.ELI and cable of causing AIDS. The cDNA and antigens of the LAV.sub.ELI virus can be used for the diagnosis of AIDS an pre-AIDS.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: May 5, 1998
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Pierre Sonigo, Simon Wain-Hobson, Luc Montagnier
  • Patent number: 5698392
    Abstract: Nucleic acid fragments derived from the HHV6 virus genome, vectors containing said fragments, and their use in the diagnosis of infections involving this virus.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 16, 1997
    Assignees: Institute Pasteur, University Paris-VI
    Inventors: Helene Collandre, Luc Montagnier, Henri Agut, Jean-Marie Bechet
  • Patent number: 5688646
    Abstract: Novel mycoplasmas are described which are prominent in patients who are thought to be suffering from AIDS. Devices are also provided for the in vitro detection of mycoplasmas in biological fluid by means of a reagent which is specific for the mycoplasma group without being specific for particular species within said group. Devices for testing mycoplasma sensitivity to antibiotics are also described.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 18, 1997
    Assignee: Institut Pasteur
    Inventors: Luc Montagnier, Alain Blanchard, Anne Marie Di Rienzo, Denise Guetard, Veronique Rame
  • Patent number: 5688637
    Abstract: The invention relates to nucleotidic sequences derived from genomes of the HIV-1 type virus, or from genomes of the HIV-2 type virus, or of the SIV type virus, and their applications, especially as oligo-nucleotidic initiators of implementation of an $i (in vitro) method for the diagnosis of the infection of an individual by a virus of the HIV-1 and/or HIV-2 type.
    Type: Grant
    Filed: December 2, 1993
    Date of Patent: November 18, 1997
    Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale
    Inventors: Maurice Moncany, Luc Montagnier